These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 16157940

  • 1. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.
    J Clin Oncol; 2005 Oct 20; 23(30):7536-45. PubMed ID: 16157940
    [Abstract] [Full Text] [Related]

  • 2. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.
    Clin Cancer Res; 2008 Feb 01; 14(3):797-803. PubMed ID: 18245541
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.
    Clin Cancer Res; 2005 Oct 15; 11(20):7470-9. PubMed ID: 16243821
    [Abstract] [Full Text] [Related]

  • 4. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.
    Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE.
    J Am Coll Surg; 2010 Feb 15; 210(2):140-7. PubMed ID: 20113933
    [Abstract] [Full Text] [Related]

  • 5. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE.
    Cancer; 2008 Oct 01; 113(7):1666-75. PubMed ID: 18726994
    [Abstract] [Full Text] [Related]

  • 6. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE.
    J Am Coll Surg; 2009 Feb 01; 208(2):193-201. PubMed ID: 19228530
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.
    Cancer; 2006 Jun 01; 106(11):2309-17. PubMed ID: 16596621
    [Abstract] [Full Text] [Related]

  • 8. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.
    Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.
    Clin Cancer Res; 2006 Jan 15; 12(2):478-86. PubMed ID: 16428490
    [Abstract] [Full Text] [Related]

  • 9. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.
    Breast Cancer Res Treat; 2006 Jul 15; 98(1):17-29. PubMed ID: 16758122
    [Abstract] [Full Text] [Related]

  • 10. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE.
    J Clin Oncol; 2008 Jul 10; 26(20):3426-33. PubMed ID: 18612158
    [Abstract] [Full Text] [Related]

  • 11. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG.
    Clin Cancer Res; 2002 Nov 10; 8(11):3407-18. PubMed ID: 12429628
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
    Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE.
    Surgery; 2006 Mar 10; 139(3):407-18. PubMed ID: 16546506
    [Abstract] [Full Text] [Related]

  • 13. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
    Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan IA, Shrivasta S, McLeod DG, Moul JW, Peoples GE.
    Int J Oncol; 2004 Dec 10; 25(6):1769-80. PubMed ID: 15547716
    [Abstract] [Full Text] [Related]

  • 14. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
    Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE.
    Ann Surg Oncol; 2007 Dec 10; 14(12):3359-68. PubMed ID: 17906897
    [Abstract] [Full Text] [Related]

  • 15. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Benavides LC, Gates JD, Carmichael MG, Patil R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE.
    Clin Cancer Res; 2009 Apr 15; 15(8):2895-904. PubMed ID: 19351776
    [Abstract] [Full Text] [Related]

  • 16. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE.
    Cancer; 2012 May 15; 118(10):2594-602. PubMed ID: 21989902
    [Abstract] [Full Text] [Related]

  • 17. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL, Schiffman K, Cheever MA, Disis ML.
    Clin Cancer Res; 2002 May 15; 8(5):1014-8. PubMed ID: 12006513
    [Abstract] [Full Text] [Related]

  • 18. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
    Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE.
    Ann Oncol; 2014 Sep 15; 25(9):1735-1742. PubMed ID: 24907636
    [Abstract] [Full Text] [Related]

  • 19. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML, Grabstein KH, Sleath PR, Cheever MA.
    Clin Cancer Res; 1999 Jun 15; 5(6):1289-97. PubMed ID: 10389911
    [Abstract] [Full Text] [Related]

  • 20. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L, Xie Y, Ahmed KA, Ahmed S, Sami A, Chibbar R, Xu Q, Kane SE, Hao S, Mulligan SJ, Xiang J.
    Breast Cancer Res Treat; 2013 Jul 15; 140(2):273-84. PubMed ID: 23881522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.